Seladelpar for previously treated primary biliary cholangitis [ID6429]
In development
Reference number: GID-TA11540
Expected publication date: TBC
The company, Gilead, has asked to submit additional evidence for this appraisal and NICE has agreed to accept this.
This additional evidence will be considered at a further committee meeting on 6 May 2026.